PortfoliosLab logoPortfoliosLab logo
MediciNova, Inc. (MNOV)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US58468P2065
CUSIP
58468P206
IPO Date
Feb 8, 2005

Highlights

Market Cap
$67.22M
Enterprise Value
$36.80M
EPS (TTM)
-$0.24
Total Revenue (TTM)
$409.66K
Gross Profit (TTM)
$31.05K
EBITDA (TTM)
-$13.28M
Year Range
$1.13 - $1.96
ROA (TTM)
-26.31%
ROE (TTM)
-28.85%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


MediciNova, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in MediciNova, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

MediciNova, Inc. (MNOV) has returned 4.58% so far this year and -6.16% over the past 12 months. Over the last ten years, MNOV has returned -16.07% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


MediciNova, Inc.

1D
0.74%
1M
-5.52%
YTD
4.58%
6M
7.87%
1Y
-6.16%
3Y*
-14.08%
5Y*
-23.24%
10Y*
-16.07%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Dec 8, 2006, MNOV's average daily return is +0.06%, while the average monthly return is +0.27%. At this rate, your investment would double in approximately 21.4 years.

Historically, 47% of months were positive and 53% were negative. The best month was Feb 2013 with a return of +102.4%, while the worst month was Sep 2008 at -42.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 6 months.

On a daily basis, MNOV closed higher 43% of trading days. The best single day was Jul 27, 2020 with a return of +95.0%, while the worst single day was May 24, 2012 at -42.9%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202631.30%-15.70%-5.52%4.58%
2025-5.71%-17.17%-10.98%4.11%-8.55%-5.76%1.15%-1.13%-3.05%30.71%-12.65%-9.66%-37.62%
2024-6.00%-4.26%7.41%-11.03%5.43%5.88%-6.94%11.94%40.00%-20.00%23.21%1.45%40.00%
202316.59%-7.95%-1.82%-2.31%1.90%6.98%3.48%2.52%-14.34%-8.61%-5.24%-17.13%-26.83%
2022-9.70%-1.24%11.72%-0.00%-8.99%4.12%-8.70%-7.79%1.88%-5.99%29.41%-22.35%-23.51%
20219.70%-3.29%-9.50%-13.07%-3.87%0.71%-14.59%7.71%-3.07%-11.35%-2.38%-18.29%-49.05%

Benchmark Metrics

MediciNova, Inc. has an annualized alpha of 11.43%, beta of 0.53, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since December 11, 2006.

  • This stock participated in 128.37% of S&P 500 Index downside but only 45.45% of its upside — more exposed to losses than it benefited from rallies.
  • Beta of 0.53 may look defensive, but with R² of 0.02 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
11.43%
Beta
0.53
0.02
Upside Capture
45.45%
Downside Capture
128.37%

Return for Risk

Risk / Return Rank

MNOV ranks 37 for risk / return — below 37% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


MNOV Risk / Return Rank: 3737
Overall Rank
MNOV Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
MNOV Sortino Ratio Rank: 3939
Sortino Ratio Rank
MNOV Omega Ratio Rank: 3838
Omega Ratio Rank
MNOV Calmar Ratio Rank: 3535
Calmar Ratio Rank
MNOV Martin Ratio Rank: 3535
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for MediciNova, Inc. (MNOV) and compare them to a chosen benchmark (S&P 500 Index).


MNOVBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.09

0.90

-0.99

Sortino ratio

Return per unit of downside risk

0.42

1.39

-0.97

Omega ratio

Gain probability vs. loss probability

1.05

1.21

-0.16

Calmar ratio

Return relative to maximum drawdown

-0.18

1.40

-1.58

Martin ratio

Return relative to average drawdown

-0.33

6.61

-6.93

Explore MNOV risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


MediciNova, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the MediciNova, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the MediciNova, Inc. was 92.09%, occurring on Aug 7, 2024. The portfolio has not yet recovered.

The current MediciNova, Inc. drawdown is 90.41%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.09%Dec 29, 20064430Aug 7, 2024
-6.55%Dec 14, 20062Dec 15, 20064Dec 21, 20066
-5.57%Dec 22, 20063Dec 27, 20061Dec 28, 20064
-0.83%Dec 11, 20061Dec 11, 20061Dec 12, 20062

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of MediciNova, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how MediciNova, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for MNOV relative to other companies in the Biotechnology industry. Currently, MNOV has a P/S ratio of 164.0. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for MNOV in comparison with other companies in the Biotechnology industry. Currently, MNOV has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items